Neumora Therapeutics, Inc. (NMRA – Research Report) received a Hold rating and price target from William Blair analyst Myles Minter ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S.

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

The global PFAS Testing Market, valued at US$379.2 million in 2023, is forecasted to grow at a robust CAGR of 14.5%, reaching US$429.2 million in 2024 and an impressive US$969.5 million by 2030. The ...

Axsome Therapeutics (AXSM) stock gains as company settles patent dispute with Hikma (HKMPF) over sleep therapy Sunosi. Read ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective hoisted by stock analysts at Robert W. Baird from ...

Axsome Therapeutics (NASDAQ:AXSM) said on Monday that in the FDA meeting minutes, the agency has supported a supplemental NDA ...

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc.